Addex Therapeutics Ltd

Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.